You're viewing an archived version of this project. Please visit the new Big Give site to find current fundraising campaigns.
Equipment for research into causes of blindness
The latest generation cutting edge equipment is needed in Bristol to determine the efficacy of novel drugs and the effect of cell based therapies towards regenerating the retina for research into the commonest causes of blindness.
December 2010 - December 2011
Charity information: National Eye Research Centre
The commonest causes of blindness in the western world are due to abnormalities of the retinal vasculature. Firstly, diabetic retinopathy results from danage to retinal blood vessels and this occurs in many diabetics. Secondly: advanced age-related macular degeneration resulting in loss of vision in 26,000 patients per year in the UK; and finally, inflammatory eye diseases, which are a leading cause of blindness in the worked age group.
The equipment we are seeking support to purchase will enable researchers to:
* characterise the evolution of retinal vascular pathology;
* detect immune cells that track through the retinal circulation;
* determine the true efficacy of the novel drugs that are developed in our laboratories to prevent blindness;
* determine effect of cell based therapies toward regenerating the retiina.
Provide the latest generation cutting edge equipment for eye research.
Activities» Approach certain Charitable Trusts to fund or part fund this equipment.
» Make a general appeal to the charity's supporters to contribute towards the cost of this equipment.
» Run specific fundraising events to support the purchase of this equipment.
» Use as small amount as possible from the charity's reserves to part-fund this equipment.
What success will look like
Success will be... the development of new therapies and drug treatments and the publication of research findings.
The research which will be advanced by this equipment has the potential to cure currently incurable eye conditions and generally impove patient eye care.
All laboratory eye research has some risks but these are monitored by the University of Bristol and all new drugs and treatments are extensively tested before their clinical use.
All donors will receive a written 'Thank You' and follow up reports will be included in annual Newsletters and the charity's Annual Report.
Budget - Project Cost: £50,000Loading graph....
Amount Heading Description £50,000 Equipment Haag-Streit Spectralis HRH+OCT FA/ICGA machine
The Inflammatory Research Group of the University of Bristol is world renowned for is success in translating advances in laboratory models of ocular diseases for the benefit of patients in the clinic. It has established an international reputation for its work on vascular degeneration and angiogenesis and given its strength of expertise and environment is ideally placed to capitalise on emerging imaging technologies and visualise the retina and its blood supply in unprecendented detail.
Sufferers from the most common causes of sight loss include Diabetic Retinopathy which affects 40% of the world's 200 million diabetics. Macular Degeneration causes sight loss to 26,000 patients a year in the UK. Inflammatory Eye Diseases are the leading causes of blindness in the working age population age group.
The National Eye Research Centre is a leading charity funding eye research, mainly in Bristol, but also in other eye centres across the UK. It supports the discovery and development of new drugs and therapies that makes a real difference to patients with eye problems nationally and internationally.
Read more about the Charity running this project.
Professor Andrew Dick
Professor Andrew Dick is the Director of Research of the charity and Head of the Department of Ophthalmology of the University of Bristol.
Dr Lindsay Nicholson
Dr Lindsay Nicholson has been the Head of the Inflammatory Eye Resarch Group of the University of Bristol since 2003.
Dr Richard Lee
Dr Richard Lee is a Clinical Research Lecturer and is developing a personalised therapy for patients with Immune Diseases treated with steriods.